Recursion Pharmaceuticals (RXRX) Accumulated Expenses (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Accumulated Expenses data on file, last reported at $54.2 million in Q1 2026.

• Quarterly Accumulated Expenses fell 4.58% year-over-year to $54.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.2 million (down 4.58% YoY) and the FY2025 annual result came in at $70.2 million, down 14.22% from the prior year.
• Accumulated Expenses declined to $54.2 million in Q1 2026, from $70.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $81.9 million in Q4 2024 to a low of $23.1 million in Q1 2022.
• A 5-year average of $43.1 million and a median of $39.8 million in 2023 frame the typical range for Accumulated Expenses.
• The widest YoY moves for Accumulated Expenses: up 117.89% in 2025, down 14.22% in 2025.
• Tracing RXRX's Accumulated Expenses over 5 years: stood at $32.9 million in 2022, then surged by 41.73% to $46.6 million in 2023, then soared by 75.56% to $81.9 million in 2024, then dropped by 14.22% to $70.2 million in 2025, then retreated by 22.82% to $54.2 million in 2026.
• The last three Accumulated Expenses figures came in at $54.2 million (Q1 2026), $70.2 million (Q4 2025), and $53.1 million (Q3 2025), per Business Quant data.